Skip to main content
LUSHANG FREDA PHARMACEUTICAL CO.,LTD. logo

LUSHANG FREDA PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 600223 ISIN · CNE000001147 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,828 across all filing types
Latest filing 2025-12-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600223

About LUSHANG FREDA PHARMACEUTICAL CO.,LTD.

http://www.lshfreda.com/

Lushang Freda Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, health supplements, and high-end cosmetics. The company is recognized as a global leader in the production of sodium hyaluronate (hyaluronic acid), utilizing advanced fermentation technology to supply raw materials for medical, food, and cosmetic applications. Its product portfolio spans several therapeutic areas, including ophthalmology, orthopedics, and dermatology, with a significant focus on medical aesthetics and functional skincare. By integrating biotechnology with industrial-scale production, the company maintains a comprehensive supply chain that supports both its proprietary brands and international B2B partnerships. Key operations involve the synthesis of bioactive substances and the formulation of specialized treatments designed to improve skin health and joint mobility.

Recent filings

Filing Released Lang Actions
鲁商福瑞达医药股份有限公司第十二届董事会2025年第五次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting, including details about the meeting date, attendance, and voting results on specific proposals. It mentions upcoming shareholder meetings and related notices but does not contain financial statements or detailed financial performance data. The content focuses on board decisions and meeting arrangements rather than financial results or regulatory filings. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors.
2025-12-29 Chinese
鲁商福瑞达医药股份有限公司2026年第一次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2026 first extraordinary shareholders meeting of 鲁商福瑞达医药股份有限公司. It contains detailed proposals regarding the expected amounts of daily related-party transactions for the year 2026, including descriptions of transaction types, counterparties, pricing policies, and impact on the company. The content is clearly related to a shareholders meeting agenda and supporting materials rather than a full financial report or announcement of voting results. The document length is about 2400 characters, which is relatively short but contains substantive meeting materials. Therefore, it fits best as AGM Information (AGM-R) which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2025-12-29 Chinese
鲁商福瑞达医药股份有限公司关于公司2026年度日常关联交易预计发生金额的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected amounts of daily related-party transactions for the fiscal year 2026 by 鲁商福瑞达医药股份有限公司. It includes details about the nature of these transactions, the approval process by the board and independent directors, and the need for shareholder meeting approval. The document does not contain financial statements or comprehensive financial data but rather focuses on disclosure of related-party transaction estimates and governance procedures. It is a regulatory announcement about related-party transactions requiring shareholder approval, fitting best under the category of Regulatory Filings (RNS) as it does not match other specific report types like Annual Report or Interim Report, nor is it a voting result or management change announcement.
2025-12-29 Chinese
2025-035-鲁商福瑞达医药股份有限公司关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a notice about convening the 2026 first extraordinary general meeting of shareholders (临时股东会) for 鲁商福瑞达医药股份有限公司. It details the meeting date, voting methods, agenda items, registration procedures, and includes an authorization proxy form for voting. There is no financial data, earnings, or report content; it is an announcement about the meeting itself and voting arrangements. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-12-29 Chinese
鲁商福瑞达医药股份有限公司关于召开2025年第三季度业绩说明会的公告
Regulatory Filings Classification · 90% confidence The document is an announcement about the scheduling and details of a 2025 third quarter earnings explanation meeting (业绩说明会). It provides the date, time, participation method, and contact information for the meeting, but does not contain the actual financial results or detailed financial data itself. The document length is short (1416 characters) and it states that the third quarter report was disclosed on October 28, 2025, and that the meeting will be held on November 3, 2025, to discuss the results. This fits the pattern of an announcement for an earnings call or earnings explanation meeting rather than the earnings release itself or a full interim report. Therefore, the most appropriate classification is Call Transcript (CT) since it is about the earnings explanation meeting, but since the transcript is not included, it is an announcement of the meeting. However, the category Call Transcript (CT) is for the full transcript, not the announcement. Given the options, the best fit is Regulatory Filings (RNS) as a general announcement about the earnings explanation meeting, since it does not contain the transcript or the earnings release itself. Confidence is high due to clear description and document length.
2025-10-27 Chinese
鲁商福瑞达医药股份有限公司关于2025年第三季度主要经营数据的公告
Regulatory Filings Classification · 85% confidence The document is an announcement from 鲁商福瑞达医药股份有限公司 regarding its main operating data for the third quarter of 2025. It includes detailed production, sales, revenue, and price changes for products and raw materials during the quarter. The document is relatively short (1457 characters) and focuses on quarterly operational data rather than comprehensive financial statements or management analysis. It does not contain full financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory announcement of key operating metrics for the quarter, which aligns with a Regulatory Filings (RNS) classification as it is a general regulatory announcement disclosing operational data without full financial reporting.
2025-10-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.